Table 2. Effect of fenoldopam and βCD on cAMP accumulation in LR and non-LR fractions.

Treatment	cAMP acculmulation (pmol/mg protein/min)
	HEK-hDjR	HEK-hD5R
Con-LRs	30.5±2.1	35.3 ±2.9
Fen-LRs	512.5 ±47.4*#	131.9±9.1*
βCD-LRs	19.7±1.0	23.4 ±3.4
βCD+Fen-LRs	185.3 ±9.8$	40.3 ±3.6
Con-non-LRs	29.6 ±3.3	54.9 ±5.0&
Fen-non-LRs	50.0±5.1	88.7 ± 5.8**
βCD-non-LRs	25.4 ±2.0	67.1 ±8.3&
βCD+Fen-non-LRs	48.2 ±3.4	68.9 ± 5.3

Cell sucrose gradient fractions 2-6 and 7-12 were combined as LR (2-6) and non-LR (7-12) fractions. The amount of cAMP in each well was measured using cAMP assay kit. cAMP accumulation was calculated and corrected for total protein (mg/ml) and expressed as pmol/mg protein/min. Values are Mean ± SEM (n = 4/group).

^*P<0.001, vs. all others in HEK-hD₁R and HEK-hD₅R cells, respectively,

^#P<0.001, vs. HEK-hD₅R,

^$P<0.001, vs. others HEK-hD₁R, and βCD+Fen-LRs HEK-hD₅R cells,

^**P<0.05, vs. all others except βCD+Fen-LRs HEK-hD₅R cells, ANOVA, Tukey test,

^&P<0.006, vs. Con-non-LRs and βCD-non-LRs, HEK-hD₁R, t-test.